{
    "nct_id": "NCT04096326",
    "official_title": "A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines",
    "inclusion_criteria": "-Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (at least 10 weeks after study intervention).\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Known immunization or hypersensitivity to any botulinum neurotoxin serotype\n* Any medical condition that may put the participant at increased risk with exposure to AGN-151586, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function\n* Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or the inability to substantially lessen facial lines even by physically spreading them apart, as determined by the investigator\n* Any brow or eyelid ptosis, as determined by the investigator\n* Infection or skin disorder at the injection sites\n* History of facial nerve palsy\n* Any uncontrolled systemic disease\n* Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study intervention)\n* Anticipated need for surgery or overnight hospitalization during the study\n* Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid [blepharoplasty] and/or eyebrow surgery)\n* Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-TexÂ®), and/or autologous fat transplantation\n* Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Screening",
    "miscellaneous_criteria": ""
}